Search results for "hcv"

showing 10 items of 277 documents

A mathematical model by route of transmission and fibrosis progression to estimate undiagnosed individuals with HCV in different Italian regions.

2022

Abstract Background Although an increase in hepatitis C virus (HCV) prevalence from Northern to Southern Italy has been reported, the burden of asymptomatic individuals in different Italian regions is currently unknown. Methods A probabilistic approach, including a Markov chain for liver disease progression, was applied to estimate current HCV viraemic burden. The model defined prevalence by geographic area using an estimated annual historical HCV incidence by age, treatment rate, and migration rate from the Italian National database. Viraemic infection by age group was estimated for each region by main HCV transmission routes of individuals for stage F0–F3 (i.e. patients without liver cirr…

Antiviral AgentLiver CirrhosisHepaciviruLiver CirrhosiResearchMarkov chainUndiagnosedInfectious and parasitic diseasesRC109-216HepacivirusHepatitis C ChronicModels TheoreticalAntiviral AgentsHepatitis CInfectious DiseasesHCVPrevalenceHumansHepatitis C infectionHumanBMC infectious diseases
researchProduct

Antiviral treatment in patients with indolent B-cell lymphomas associated with HCV infection: a study of the Fondazione Italiana Linfomi

2014

Antiviral Treatment indolent B cell lymphomaHCv infection
researchProduct

Hepatic steatosis and insulin resistance are associated with severe fibrosis in patients with chronic hepatitis caused by HBV or HCV infection.

2011

BACKGROUND AND AIMS: Steatosis and insulin resistance (IR) are the major disease modifying in patients with chronic hepatitis C (CHC). Only few studies evaluated these features in patients with chronic hepatitis B (CHB). We aimed to assess the prevalence and the factors related to steatosis and IR in CHB patients, compared with CHC subjects, and to evaluate the potential association between these features and fibrosis severity. MATERIAL AND METHODS: One hundred and seventy consecutive patients with CHB (28 HBeAg positive, 142 HBeAg negative), were evaluated using liver biopsy and metabolic measurements and matched for sex, age and body mass index with 170 genotype 1 CHC patients. IR was def…

Blood GlucoseLiver CirrhosisMaleSettore MED/09 - Medicina InternaBiopsyEnzyme-Linked Immunosorbent AssaySettore MED/08 - Anatomia PatologicaSettore MED/13 - EndocrinologiaBody Mass IndexteatosisHBVPrevalenceHumansInsulinHepatitis B AntibodiesTriglyceridesImmunoassaySettore MED/12 - GastroenterologiaHBV;HCV;steatosisAlanine TransaminaseHepatitis BHepatitis CFatty LiverItalyHCVRegression AnalysisFemaleInsulin ResistanceLiver international : official journal of the International Association for the Study of the Liver
researchProduct

Are blood donors an adequate control group to ascertain HCV prevalence in non-Hodgkin’s lymphoma patients?

2002

Blood donorSettore MED/09 - Medicina Internanon-Hodgkin’s lymphomaHCV prevalence
researchProduct

Affidabilità del bright liver nella diagnosi di steatosi epatica in pazienti con infezione da virus dell'immunodeficienza acquisita (HIV), da virus d…

2009

Bright liver steatosi ecografia HIV HCV coinfezione
researchProduct

Reply.

2013

CAROTID ATHEROSCLEROSIS HCV
researchProduct

The impact of DAA-mediated HCV eradication on CD4+ and CD8+ T lymphocyte trajectories in HIV/HCV coinfected patients: Data from the ICONA Foundation …

2021

HCV infection has been hypothesized as a contributor of poor CD4+ recovery in patients living with HIV (PLWHIV). Aim of this study was to evaluate CD4+, CD8+ cells and CD4/CD8 ratio trends before and after HCV treatment with direct acting agents (DAA) in PLWHIV. HIV/HCV patients enrolled in ICONA and HepaICONA cohorts with HIV-RNA≤50 copies/ml who achieved a sustained viral response after DAA treatment were studied. A linear regression model was used to investigate CD4+, CD8+ and CD4/CD8 changes 12 months before and after DAA treatment. A total of 939 HIV/HCV patients were included, 225 (24.0%) female, median age: 53 years (IQR 50–56). At DAA initiation, CD4+ T cell count was <350 cells/…

CD4-Positive T-LymphocytesHIV InfectionsHepacivirusCD8-Positive T-LymphocytesGastroenterologySettore MED/07chemistry.chemical_compound0302 clinical medicineCd8 t lymphocyteHIV Infection030212 general & internal medicineCoinfectionCD4; CD8; DAA; HCV/HIV; immune activationHcv clearancevirus diseasesMiddle AgedHepatitis CInfectious Diseasesmedicine.anatomical_structureCD4-Positive T-LymphocyteCohort030211 gastroenterology & hepatologyFemaleCD4 CD8 DAA HCV/HIV immune activationHumanImmune activationmedicine.medical_specialtyHCV/HIVT cellAntiviral Agentsimmune activationNO03 medical and health sciencesVirologyInternal medicinemedicineHumansIn patientimmune activation.DAAAntiviral AgentHepaciviruHepatologybusiness.industryRibavirinCD8-Positive T-LymphocyteCD8CD4CD4 Lymphocyte CountchemistryCD4; CD8; DAA; HCV/HIV; immune activation; Antiviral Agents; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Female; Hepacivirus; Humans; Middle Aged; Coinfection; HIV Infections; Hepatitis CbusinessCD8
researchProduct

EFFICACY AND SAFETY OF BOCEPREVIR-BASED THERAPY IN HCVG1 TREATMENT-EXPERIENCED PATIENTS WITH ADVANCED FIBROSIS/CIRRHOSIS: THE ITALIAN AND SPANISH NPP…

2014

Background and Aims: To maximize cost/efficay of boceprevirbased triple therapy (BOC) in patients with HCV-related advanced fibrosis/cirrhosis. Methods: ITT SVR12, safety and futility rules value were evaluated in the multicenter national Italian and Spanish early access Name- Patient-Program which includes treatment-experienced patients with HCVG1-related advanced fibrosis/cirrhosis (Metavir F3/4) treated with BOC in both countries. Results: 402 patients (mean age 55 years; range 22–75), 316 (78.6%) G1b, 255 (63.4%) F4, 60 (30.9%) with oesophageal varices, 137 (34.1%) relapsers, 95 (23.6%) partial and 168 (41.8%) null responders were enrolled. Platelets count <100,000 and albumin levels <3…

CHRONIC HCVSettore MED/12 - GastroenterologiaSettore MED/09 - Medicina InternaHEPATITIS CCIRRHOSISHEPATITIS C; CIRRHOSIS; CHRONIC HCV
researchProduct

Carotid atherosclerosis and chronic hepatitis C: A prospective study of risk associations

2011

BACKGROUND AND AIMS: There are contrasting results in studies of cardiovascular risk in patients with genotype 1 chronic hepatitis C (G1 CHC). We evaluated the prevalence of carotid atherosclerosis compared with a control population in order to assess the potential association between atherosclerosis, host and viral factors, and liver histological features. MATERIALS AND METHODS: One hundred seventy-four consecutive biopsy-proven G1 CHC patients were evaluated by anthropometric and metabolic measurements. One hundred seventy-four patients attending an outpatient cardiology unit were used as controls. Intima-media thickness (IMT) and carotid plaques, defined as focal thickening of > 1.3 mm a…

Carotid Artery DiseasesMaleLIVER BIOPSYComorbiditySeverity of Illness IndexGastroenterologyBody Mass IndexReference ValuesOdds RatioPrevalenceProspective StudiesProspective cohort studySettore MED/12 - Gastroenterologiamedicine.diagnostic_testBiopsy NeedleSmokingHepatitis CMiddle AgedPrognosisHCV ATHEROSCLEROSI FIBROSISImmunohistochemistryItalyCAROTID ATHEROSCLEROSISFemaleRadiologyAdultmedicine.medical_specialtySettore MED/08 - Anatomia PatologicaCHRONIC HEPATITIS CRisk AssessmentYoung AdultAge DistributionInternal medicineDiabetes mellitusBiopsyHEPATIC FIBROSISConfidence IntervalsmedicineHumansObesitySex DistributionAgedAnalysis of VarianceHepatologybusiness.industryCase-control studyUltrasonography DopplerOdds ratioHepatitis C ChronicHepatologymedicine.diseaseDiabetes Mellitus Type 2Case-Control StudiesMultivariate AnalysisLinear ModelsSteatosisbusinessHepatology
researchProduct

Assessment of health-related quality of life of chronic hepatitis C patients in Latvia

2019

Šā pētījuma mērķis ir novērtēt hroniska C hepatīta pacientu ar veselību saistīto dzīves kvalitāti Latvijā, izmantojot anketu par aknu slimībām, un izpētīt jomas, kurās visbiežāk ir traucēta ar veselību saistītā dzīves kvalitāte. Šajā pētījumā tiks arī apskatīti faktori, kas saistīti ar hroniska C hepatīta pacientu dzīves kvalitāti. Šis ir prospektīvs novērojumu pētījums. Hronisko aknu slimību anketa tika pielāgota un izsniegta Latvijas Infektoloģijas centra pacientiem, kam ir seroloģiski apstiprināts hronisks C vīrushepatīts. Kontroles grupā tika iekļauti pieauguši latvieši, kuriem nav diagnosticēts hronisks C vīrushepatīts Pētījuma tika iekļauti 80 pacienti vecumā no 25 līdz 78 gadiem (vid…

Chronic liver disease questionnaireHealth-related quality of lifeHCVChronic hepatitis CMedicīna
researchProduct